Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy

Hydration Intervention to Address Dehydration Associated With Use of GLP-1 Based Medications

This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.

Inclusion Criteria:

• Adults aged 18-60
• Recently prescribed a GLP-1RA (within one week of prescription)
• Fluent in English
• Willing to complete the study protocol

Exclusion Criteria:

• Children and adults > 60 years of age
• Those not taking a GLP-1RA
• Those who have been on a GLP-1RA longer than one week
• Not fluent in English
• Those who are pregnant or planning on becoming pregnant during the duration of the study
• Unwilling to comply with study protocol
• People with cardiac implants